{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T22:22:07Z","timestamp":1776637327098,"version":"3.51.2"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.bbrc.2015.06.077","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T21:34:17Z","timestamp":1434663257000},"page":"1165-1175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of novel hepatitis B virus capsid inhibitor using in silico screening"],"prefix":"10.1016","volume":"463","author":[{"given":"Michiyo","family":"Hayakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuo","family":"Iwadate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihito","family":"Tanahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Tamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2015.06.077_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"G.\u00a0Taiwan Community-Based Cancer Screening Project, Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2015.06.077_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/0140-6736(93)92249-S","article-title":"Molecular virology and pathogenesis of hepatitis B","volume":"342","author":"Lau","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2015.06.077_bib3","doi-asserted-by":"crossref","first-page":"e8093","DOI":"10.1371\/journal.pone.0008093","article-title":"Mechanism for CCC DNA synthesis in hepadnaviruses","volume":"4","author":"Sohn","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2015.06.077_bib4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.bbrc.2015.06.077_bib5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1179\/joc.2008.20.4.458","article-title":"Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly","volume":"20","author":"Wu","year":"2008","journal-title":"J.\u00a0Chemother."},{"key":"10.1016\/j.bbrc.2015.06.077_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.antiviral.2011.08.012","article-title":"The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in\u00a0vitro to non-nucleoside inhibitors of HBV replication","volume":"92","author":"Billioud","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bbrc.2015.06.077_bib7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly","volume":"19","author":"Stray","year":"2006","journal-title":"J.\u00a0Mol. Recognit."},{"key":"10.1016\/j.bbrc.2015.06.077_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2014.11.024","article-title":"Discovering novel direct acting antiviral agents for HBV using in silico screening","volume":"456","author":"Murakami","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2015.06.077_bib9","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A\u00a0unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2015.06.077_bib10","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2015.06.077_bib11","doi-asserted-by":"crossref","first-page":"9134","DOI":"10.1158\/0008-5472.CAN-05-4290","article-title":"KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties","volume":"66","author":"Nakamura","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2015.06.077_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/157340606776056160","article-title":"FAMS complex: a fully automated homology modeling system for protein complex structures","volume":"2","author":"Takeda-Shitaka","year":"2006","journal-title":"Med. Chem."},{"key":"10.1016\/j.bbrc.2015.06.077_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jhep.2005.10.028","article-title":"Growth and differentiation of colony-forming human hepatocytes in\u00a0vitro","volume":"44","author":"Yamasaki","year":"2006","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.bbrc.2015.06.077_bib14","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1128\/JCM.37.9.2899-2903.1999","article-title":"Quantitation of hepatitis B virus genomic DNA by real-time detection PCR","volume":"37","author":"Abe","year":"1999","journal-title":"J.\u00a0Clin. Microbiol."},{"key":"10.1016\/j.bbrc.2015.06.077_bib15","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.42.12.3179","article-title":"Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine","volume":"42","author":"King","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2015.06.077_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2007.06.014","article-title":"The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging","volume":"76","author":"Feld","year":"2007","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2015.06.077_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0166-3542(01)00216-9","article-title":"Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model","volume":"54","author":"Weber","year":"2002","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2015.06.077_bib18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1126\/science.1077215","article-title":"Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids","volume":"299","author":"Deres","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2015.06.077_bib19","doi-asserted-by":"crossref","first-page":"e25096","DOI":"10.1371\/journal.pone.0025096","article-title":"Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA\/SCID mice","volume":"6","author":"Brezillon","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2015.06.077_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3851\/IMP2152","article-title":"In\u00a0vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations","volume":"17","author":"Wang","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bbrc.2015.06.077_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.toxlet.2007.07.010","article-title":"NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats","volume":"173","author":"Shi","year":"2007","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.bbrc.2015.06.077_bib22","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.bcp.2003.08.001","article-title":"Antivirals interacting with hepatitis B virus core protein and core mutations may misdirect capsid assembly in a similar fashion","volume":"66","author":"Hacker","year":"2003","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15301303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X15301303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T20:19:48Z","timestamp":1599164388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X15301303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0006291X15301303"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.077","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of novel hepatitis B virus capsid inhibitor using in silico screening","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2015.06.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}